

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

EUROPEAN PATENT APPLICATION
published in accordance with Art.
158(3) EPC

Application number: 89910671.0

Int. Cl.⁵: C07D 495/04, A61K 31/50

Date of filing: 20.09.89

International application number:
PCT/JP89/00956

International publication number:
WO 90/03380 (05.04.90 90/08)

Priority: 21.09.88 JP 237600/88

Date of publication of application:
31.10.90 Bulletin 90/44

Designated Contracting States:
AT BE CH DE FR GB IT LI NL SE

Applicant: YOSHITOMI PHARMACEUTICAL
INDUSTRIES, LTD.
6-9, Hiranomachi 2-chome Chuo-ku
Osaka-shi Osaka 541(JP)

Inventor: NAKAO, Tohru
774-22, Oaza-Higashihama Nakatsu-shi
Oita 871(JP)
Inventor: TANAKA, Hiroshi 345, Oaza-Naoue

Yoshitomi-machi Chikujo-gun
Fukuoka 871(JP)


Inventor: MORIMOTO, Yasuto
26-7, Oaza-Ushigami Nakatsu-shi
Oita 871(JP)

Inventor: TAKEHARA, Shuzo 684-1,
Shimomiyana 3-chome
Nakatsu-shi
Oita 871(JP)

Representative: von Kreisler, Alek,
Dipl.-Chem. et al
Patentanwälte Von Kreisler-Selting-Werner,
Deichmannhaus am Hauptbahnhof
D-5000 Köln 1(DE)

THIENOCYCLOHEPTAPYRIDAZINE COMPOUNDS AND MEDICINAL USES THEREOF.

(I)



(I)

EP 0 394 471 A1

Thienocycloheptapyridazine compounds represented by general formula (I), wherein R represents hydrogen, halogen or C₁₋₄ alkyl, Ar represents aryl or heteroaryl which may have at least one substituent selected from among halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, amino, hydroxy, trifluoromethyl and C₂₋₅ alkanoyl, and a bond ---- between the 6a-position and the 7-position represents a single or double bond are disclosed. The compounds are useful as an anti-anxiety agent, amnesia treating agent, brain function

activating agent or dementia treating agent.

SPECIFICATION

Thienocycloheptapyridazine Compounds and their Pharmaceutical Use
[Technical Field]

This invention relates to thienocycloheptapyridazine compounds which are novel and of use as pharmaceuticals and their pharmaceutical use.

[Background Art]

Benzodiazepine (BZP) derivatives represented by diazepam have been used long as an antianxiety drug or a therapeutic medicine for sleep disturbance. The recent pharmacological studies have shown that there exist receptors which exhibit a specific affinity for BZP derivatives in the central nervous system [Science, vol. 198, 849 (1977)]. In the studies and researches conducted subsequently, there have been investigated and developed not only BZP derivatives but also the compounds which have structures different from BZP but exhibit a high affinity for BZP receptors and a BZP-like action (BZP agonist), the compounds which exhibit a high affinity for BZP receptors but exhibit a pharmacological action reverse to BZP (BZP inverse-agonist) and the compounds which exhibit a high affinity for BZP receptors but nevertheless exhibit no pharmacological activity themselves and rather show an antagonistic action against the action of the agonist or the inverse-agonist (BZP antagonist) [Advance in Drug Research, vol. 14, 165 (1985)].

Since BZP derivatives which are used as an antianxiety

drug have a sedative action, a muscle-relaxing action and an anticonvulsive action in addition to an antianxiety action, they often cause troubles in terms of side effects such as dizziness and sleepiness. Thus, researches of non-BZP types of compounds aiming at developing selective antianxiety drugs with less side effects are thriving. Nevertheless, there have not been found satisfactory ones yet.

Also, in recent years, amnesia-inducing actions by BZP agonists were found [Nature, vol. 321, 864 (1986)], and there have been reports suggesting the possibility that BZP-antagonists exhibiting an antagonistic action against the amnesic actions induced by BZP agonists and BZP-inverse-agonists exhibiting an action reverse to the amnesic actions by BZP agonists are usable as brain-function activating drugs. [Trends in Neurosciences, vol. 11, 13 (1988)].

In the meantime, in the specification of U.S. Patent No. 4602019 there are disclosed compounds such as 2,4,4a,5-tetrahydro-7-(1H-imidazol-1-yl)-3H-indeno[1,2-c]pyridazin-3-one having a cardiac action and an antihypertensive action. The Journal of Medicinal Chemistry, vol. 24, 830 (1981) discloses compounds such as 2-(4-chlorophenyl)benzothiopyrano-[4,3-c]pyrazol-3-one possessing an immune-suppressing action.


[Disclosure of Invention]

The present inventors have conducted intensive studies for the purpose of developing BZP-agonists, BZP-inverse-agonists or BZP-antagonists having a non-BZP-nucleus which

are useful pharmaceuticals and providing effective compounds and pharmaceuticals.

It has been found that the above-mentioned purpose can be attained according to the present invention described hereinafter.

That is, the first invention is to provide thienocycloheptapyridazine compounds of the formula



wherein R stands for hydrogen, a halogen or a C₁₋₄ alkyl, Ar stands for an aryl, a heteroaryl, or an aryl or a heteroaryl having as a substituent at least a halogen, a C₁₋₄ alkyl, a C₁₋₄ alkoxy, nitro, amino, hydroxy, trifluoromethyl and/or a C₂₋₅ alkanoylamino; and the bond ----- between 6a-position and 7-position represents a single bond or a double bond.

The second invention is to provide pharmaceutical compositions comprising a thienocycloheptapyridazine compound of the above formula (I).


The symbols of the formula (I) and each of the below-mentioned formulae are defined in detail below. The halogen represents chlorine, bromine, fluorine or the like; the C₁₋₄ alkyl represents methyl, ethyl, propyl, isopropyl, butyl,

isobutyl or tert-butyl; the C₁₋₄ alkoxy represents methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy or tert-butoxy; the C₂₋₅ alkanoylamino represents acetylamino, propionylamino, butyrylamino or pivaloylamino; the aryl represents phenyl, naphthyl or the like; and the heteroaryl represents a 5- or 6-membered ring or its fused ring containing 1 to 3 (preferably 1 or 2) hetero atom(s) (e.g. nitrogen, oxygen, sulfur) on the ring such as 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 3- or 4-pyrazolyl, 1- or 2-imidazolyl, 2-, 4- or 5-pyrimidinyl, 3-, 4- or 5-pyridazinyl or 2-, 4- or 5-benzimidazolyl.


Preferable compounds of the present invention are the compounds selected from the group consisting of 9-(4-chlorophenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methylphenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-phenyl-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methoxyphenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-chlorophenyl)-5,6-dihydro-2-methyl-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-chlorophenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(6-chloro-2-pyridyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methylphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-

methoxyphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta-[1,2-c]pyridazin-8(9H)-one, 2-bromo-9-(4-chlorophenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 2-bromo-9-(4-methoxyphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one and 2-bromo-9-(4-chlorophenyl)-5,6-dihydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one.


The compounds of the formula (I) can be produced by subjecting to ring-closure reaction a compound of the formula



wherein each of the symbols is as defined above, which can be obtained by reacting a compound of the formula



wherein R is as defined above, with a hydrazine derivative of the formula



(III)

wherein Ar is defined as above or its acid addition salt.

The reactions proceed by heating under reflux in a suitable solvent, for example, an alcohol solvent such as methanol, ethanol or propanol, or inert solvent such as benzene or toluene for 5 to 20 hours to yield the compound of the formula (I) and the compound of the formula (IV).

In case where an acid addition salt of the hydrazine derivative of the formula (III) is employed, the reaction is conducted in the presence of an acid scavenger (sodium acetate, potassium acetate, sodium bicarbonate, sodium carbonate, potassium carbonate, pyridine, triethylamine, etc.).


When the compound of the formula (IV) is obtained in the above reaction, the compound of the formula (I) can be produced by heating the obtained compound of the formula (IV) under reflux in acetic acid for 5 - 10 hours.

The compound of the formula (I) wherein the bond between 6a-position and 7-position is a double bond can be synthesized also by adding bromine in an amount of 1 - 1.5 times mol dropwise to the corresponding compound of the formula (I) wherein the bond between 6a-position and 7-position is a single bond in acetic acid as the solvent at 20 - 60°C [Journal of Medicinal Chemistry, vol. 14, 262 (1971)] or by reacting the compound of the formula (I) wherein the bond between 6a-position and 7-position is a single bond with


sodium-m-nitrobenzenesulfonate (Bachmann method, The specification of United Kingdom Patent No. 1168291).

The compounds of the formula (I) which can be produced in the above-mentioned manner can be isolated and purified by a conventional method such as column chromatography or recrystallization.

The compounds of the formula (II) of this invention are novel compounds which have not been described in any literature. The compounds can be produced by, for example, converting the corresponding compounds of the formula



wherein R is as defined above, or their acid addition salts to their quaternary ammonium compounds by adding methyl iodide to the compounds of the formula (V) or their acid addition salts in acetone and retaining the mixture at room temperature for 2 - 5 hours, followed by converting the quaternary ammonium compounds to the corresponding cyano compounds of the formula



wherein R is as defined above, by adding potassium cyanide or sodium cyanide to the quaternary ammonium compounds in an aqueous methanol and reacting the mixture at 30 - 50°C for 4 - 10 hours, followed by adding the thus-obtained compounds of the formula (VI) to acetic acid and conc. hydrochloric acid and heating under reflux the mixture for 5 - 12 hours.

For reference's sake, representative examples of the compounds of the formula (II) are indicated with their physical constant below.

2-Methyl-4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-5-acetic acid, melting at 155.5 - 157.5°C.

4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-5-acetic acid, melting at 130 - 131°C.

2-Bromo-4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-5-acetic acid, melting at 129 - 131°C.

The compounds of the formula (I) exhibit a high affinity of 10^{-8} - 10^{-9} M to BZP receptors and have an antagonistic action against chemical convulsants such as bicuculline and pentylenetetrazole. They also exhibit an inhibitory action against amnesia induced by electroconvulsive shock.

The pharmacological actions of the compounds of the present invention are shown with the experimental methods therefor below.

Experimental Example 1 : Displacement ability for Benzo-diazepine

The experiment for specific affinity to benzodiazepine receptors was carried out in accordance with the method described in Life Science, vol. 20, 2101 (1977).

The crude synaptosome fraction was isolated from the cerebral cortex of male Wistar rats aged 9 - 10 weeks, and was suspended in 50 mM Tris-hydrochloric acid buffer solution (pH 7.4) containing 120 mM sodium chloride and 5 mM potassium chloride. These suspensions were used for the experiment.

The test compounds in several different concentrations and tritiated diazepam (in final concentration of 2 nM) were added to the synaptosome suspensions, and the mixtures were incubated at 0°C for 20 minutes. These suspensions were filtered with Whatman GF/B glassfiber filters. After the filters were washed with the above-mentioned buffer solution, the radioactivity left on the filters was measured with the use of a liquid scintillation counter.

Specific binding was determined by subtracting binding in the presence of 10^{-6} M unlabelled diazepam from total binding.

According to the foregoing experimental method, the binding force to benzodiazepine receptors of the compound of the present invention is evaluated from its displacement ability for tritiated diazepam at its binding site, which is represented by K_i value (nM).

The results of the experiment are shown in Table 1.

Table 1

Test compound (Example No.)	Affinity to BZP Receptors, K _i (nM)
1	4.8
4	1.1

Experimental Example 2 : Anti-Bicuculline Action

The anti-bicuculline action test was carried out in accordance with the method described in Life Science, vol. 21, 1779 (1977).

Male ddY mice weighing 20 - 28 g, 7 - 14 animals per group, were used. One hour after the oral administration of the test compounds, (+) bicuculline was intravenously administered at the dosage of 0.6 mg/kg, and 50% effective concentration (ED₅₀) was estimated by examining whether the tonic convulsion within 5 minutes was caused or not. The result was that the ED₅₀ values of the compounds of Example 1 and 5 were 8.1 mg/kg and 9.8 mg/kg, respectively.

Experimental Example 3 : Action on Experimental Amnesia

Twenty male ddY mice were used per each group to investigate the action of the test compounds on learning and memory ability of amnesia-induced mice by observing a step-through passive avoidance reflex. Amnesia-induced animals were prepared by applying electroconvulsive shock (ECS) soon after the acquisition trial and the retention test was carried out 24 hours after the acquisition trial. Test compounds were administered intraperitoneally (i.p.) 30

minutes before the acquisition trial.

As the result, it was found that the compound of Example 4 significantly prolonged the latency time in the trial of the retention test at the dose of 2.5 mg/kg (i.p.) or more and exhibited an improvement action on amnesia.

Experimental Example 4 : Acute Toxicity

Five male ddY mice were used per each group. The mice were administered with 300 mg/kg of the compound of Example 4 intraperitoneally, but all mice survived for 5 days after the administration. Similarly, the mice were orally administered with 1000 mg/kg of the compound, but they survived for 5 days after the administration.

As apparent from the foregoing various pharmacological studies including experiments, the compounds (I) of the present invention have a high affinity for BZP receptors and exhibit an antagonistic action against chemical convulsion-inducing agents such as bicuculline and pentylenetetrazole, whereas they influence to a small extent on somatic functions such as muscle-relaxing actions. Thus, they are useful as an antianxiety agent. Also, since they possess an inhibitory action on amnesia induced by electroconvulsive shock, they are useful as an amnesia-treating drugs, brain function-activating drugs and antidementiac drugs. They are also of value as an antidote for excessive administration of or toxicosis by existent antianxiety drugs such as diazepam.

When the compounds of the formula (I) are used as pharma-

ceuticals, a therapeutically effective amount of the compounds and adequate pharmacologically acceptable additives such as excipient, carrier, diluent and so on are mixed to be formulated into a form such as tablets, capsules, granules, syrups, injectable solutions, suppositories, dispersible powders or the like and are administered in a form mentioned above. The dosage, for example, in the case of oral administration, is generally about 5 - 500 mg daily per adult, which is once a day or in divided doses several times a day administered.

Below, this invention is more specifically described with working examples, which are not to be construed as limitative.

Example 1

A suspension of 2.5 g of 2-methyl-4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-5-acetic acid and 1.95 g of 4-chlorophenyl hydrazine in 50 ml of toluene is refluxed under heating for 4 hours. After cooling, the mixture is concentrated under reduced pressure and the precipitated crystals are recrystallized from ethanol to give 2.7 g of 9-(4-chlorophenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, melting at 119 - 121°C.

Example 2

The reaction and procedure are conducted in the same manner as in Example 1 using 4-methylhydrazine in place

of 4-chlorophenylhydrazine as used in Example 1 to give 9-(4-methylphenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, melting at 117 - 119°C.

Example 3

The reaction and procedure are conducted by the same method as of Example 1 using phenylhydrazine instead of 4-chlorophenylhydrazine as used in Example 1 to give 9-phenyl-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, melting at 102 - 103°C.

Example 4

The reaction and procedure are conducted by the same method as of Example 1 using 4-methoxyphenylhydrazine in place of 4-chlorophenylhydrazine as used in Example 1 to give 9-(4-methoxyphenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, melting at 136 - 138.5°C.

Example 5

To a solution of 3.6 g of 9-(4-chlorophenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one in 30 ml of acetic acid is added 0.6 ml of bromine at 40°C with stirring and the reaction mixture is stirred at 40 - 45°C for 30 minutes. The mixture is poured into water and the resultant oil is collected by decantation. The crude product is subjected to column chromatography on silica gel

and eluted with chloroform to give 1.27 g of 9-(4-chlorophenyl)-5,6-dihydro-2-methyl-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, melting at 149.5 - 151°C.

Example 6

A suspension of 2.0 g of 4-oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-5-acetic acid and 1.6 g of 4-chlorophenylhydrazine in 40 ml of ethanol is refluxed under heating for 8 hours. After cooling, the mixture is concentrated under reduced pressure and the ethanol is distilled off. The residue is dissolved in 40 ml of acetic acid and the solution is refluxed under heating for 2 hours. After distilling off the acetic acid under reduced pressure, the resultant residue is subjected to column chromatography on silica gel. The crystals obtained from the fraction which has been eluted with chloroform are recrystallized from a mixed solvent of chloroform and ethanol to give 2.0 g of 9-(4-chlorophenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one as pale brown crystals, melting at 156 - 158°C.

The following compounds can be obtained in the same manner as in the above examples.

Example 7

9-(6-Chloro-2-pyridyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, melting at 165 - 167°C.

Example 8

9-(4-Methylphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-

f]cyclohepta[1,2-c]pyridazin-8(9H)-one, melting at 105 - 107°C.

Example 9

9-(4-Methoxyphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, melting at 135 - 137°C.

Example 10

2-Bromo-9-(4-chlorophenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, melting at 129 - 131°C.

Example 11


2-Bromo-9-(4-methoxyphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, melting at 139 - 141°C.

Example 12

To a solution of 2.5 g of 2-bromo-9-(4-chlorophenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one in 40 ml of acetic acid is added a solution of 1.1 g of bromine in 5 ml of acetic acid with stirring at 40°C over a period of 10 minutes. The mixture is stirred at 40 - 50°C for 20 minutes and poured into ice-cold water. The precipitated crystals are collected by filtration, washed with water, dissolved in chloroform and subjected to column chromatography on silica gel. The crystals obtained from the fraction which has been eluted with chloroform are recrystallized from a mixed solvent of ethanol and chloroform to give 1.5 g














of 2-bromo-9-(4-chlorophenyl)-5,6-dihydro-4H-thieno[2,3-f]-cyclohepta[1,2-c]pyridazin-8(9H)-one as white crystals, melting at 143 - 144°C.

The compounds shown in the following tables can be obtained in the same manner as in the above examples.
















No.	R	Ar	6a-7 bond
13	2-CH ₃		S
14	2-CH ₃		D
15	2-CH ₃		S
16	2-CH ₃		D
17	2-CH ₃		S
18	2-CH ₃		D
19	2-CH ₃		S
20	2-CH ₃		D
21	2-CH ₃		S
22	2-CH ₃		D
23	2-CH ₃		S













S:single bond, D:double bond

No.	R	Ar	6a-7 bond
24	2-CH ₃		D
25	2-CH ₃		S
26	2-CH ₃		D
27	2-CH ₃		S
28	2-CH ₃		D
29	H		S
30	H		D
31	H		D
32	H		S
33	H		D
34	H		S
35	H		D
36	H		D

S:single bond, D:double bond

No.	R	Ar	6a-7 bond
37	H		D
38	H		S
39	H		D
40	H		S
41	H		D
42	H		S
43	H		D
44	H		S
45	H		D
46	H		S
47	H		D
48	2-Br		S
49	2-Br		D

S:single bond, D:double bond

No.	R	Ar	6a-7 bond
50	2-Br		S
51	2-Br		D
52	2-Br		S
53	2-Br		D
54	2-Br		S
55	2-Br		D
56	2-Br		S
57	2-Br		D
58	2-Br		S
59	2-Br		D
60	2-Br		S
61	2-Br		D

S:single bond, D:double bond

Formulation Example

Tablets containing 10 mg of a compound of the formula (I) are prepared in accordance with the following formulation.


Compound of formula (I)	10.0 mg
Lactose	58.5 mg
Corn starch	25.0 mg
Crystalline cellulose	20.0 mg
Polyvinylpyrrolidone K-30	2.0 mg
Talc	4.0 mg
Magnesium stearate	0.5 mg
	<hr/>
	120.0 mg

The compound of the formula (I) is pulverized by an atomizer into fine powders below 10 μ in average particle diameter, which are admixed with lactose, corn starch and crystalline cellulose sufficiently in a kneading machine, and further kneaded with polyvinylpyrrolidone paste. The kneaded mixture is passed through a sieve of 200 mesh, dried at 50°C and passed through a sieve of 24 mesh. Talc and magnesium stearate are mixed therewith and the mixture is compressed into 120.0 mg tablets with a punch of 8 mm in diameter. These tablets are, if desired, subjected to sugar-coating or film-coating.

While the present invention has been adequately and sufficiently described in the foregoing specification including examples, the description can be changed or modified within the spirit and scope of this invention.

Claims

1. A thienocycloheptapyridazine compound of the formula



wherein R is hydrogen, a halogen or a C_{1-4} alkyl, Ar is an aryl, a heteroaryl, or an aryl or a heteroaryl which has as a substituent at least a halogen, a C_{1-4} alkyl, a C_{1-4} alkoxy, nitro, amino, hydroxy, trifluoromethyl and/or a C_{2-5} alkanoylamino; and the bond ----- between 6a-position and 7-position is a single bond or a double bond.

2. A compound as claimed in Claim 1 which is selected from a group consisting of 9-(4-chlorophenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methylphenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-phenyl-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methoxyphenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-chlorophenyl)-5,6-dihydro-2-methyl-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-chlorophenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-

8(9H)-one, 9-(6-chloro-2-pyridyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methylphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methoxyphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 2-bromo-9-(4-chlorophenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 2-bromo-9-(4-methoxyphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one and 2-bromo-9-(4-chlorophenyl)-5,6-dihydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one.


3. A pharmaceutical composition comprising a compound as claimed in Claim 1 or Claim 2 and pharmaceutical additives.

4. An antianxiety drug comprising a compound as claimed in Claim 1 or Claim 2 as an effective ingredient.

5. An amnesia-treating drug, a brain function-activating drug or an antidementiac drug comprising a compound as claimed in Claim 1 or Claim 2 as an effective ingredient.

Claims (amended)

1. A thienocycloheptapyridazine compound of the formula



wherein R is hydrogen, a halogen or a C₁₋₄ alkyl, Ar is an aryl, a heteroaryl, or an aryl or a heteroaryl which has as a substituent at least a halogen, a C₁₋₄ alkyl, a C₁₋₄ alkoxy, nitro, amino, hydroxy, trifluoromethyl and/or a C₂₋₅ alkanoyl-amino; and the bond ----- between 6a-position and 7-position is a single bond or a double bond.

2. A compound as claimed in Claim 1 which is selected from a group consisting of 9-(4-chlorophenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methylphenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-phenyl-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methoxyphenyl)-2-methyl-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-chlorophenyl)-5,6-dihydro-2-methyl-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-chlorophenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-

8(9H)-one, 9-(6-chloro-2-pyridyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methylphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 9-(4-methoxyphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 2-bromo-9-(4-chlorophenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one, 2-bromo-9-(4-methoxyphenyl)-5,6,6a,7-tetrahydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one and 2-bromo-9-(4-chlorophenyl)-5,6-dihydro-4H-thieno[2,3-f]cyclohepta[1,2-c]pyridazin-8(9H)-one.

3. A pharmaceutical composition comprising a compound as claimed in Claim 1 or Claim 2 and pharmaceutical additives.

4. An antianxiety drug comprising a compound as claimed in Claim 1 or Claim 2 as an effective ingredient.

5. An amnesia-treating drug, a brain function-activating drug or an antidementiac drug comprising a compound as claimed in Claim 1 or Claim 2 as an effective ingredient.

INTERNATIONAL SEARCH REPORT

International Application No PCT/JP89/00956

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC <div style="text-align: center; margin-top: 10px;"> Int. Cl⁴ C07D495/04, A61K31/50 </div>						
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;"> Minimum Documentation Searched : <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border-bottom: 1px solid black;">Classification System</td> <td style="border-bottom: 1px solid black;">Classification Symbols</td> </tr> <tr> <td style="text-align: center; padding-top: 10px;">IPC</td> <td style="text-align: center; padding-top: 10px;">C07D495/04, A61K31/50</td> </tr> </table> </div> <div style="text-align: center; margin-top: 10px;"> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched * </div>			Classification System	Classification Symbols	IPC	C07D495/04, A61K31/50
Classification System	Classification Symbols					
IPC	C07D495/04, A61K31/50					
III. DOCUMENTS CONSIDERED TO BE RELEVANT *						
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³				
T	JP, A, 1-6278 (Yoshitomi Pharmaceutical Industries, Ltd.) 10 January 1989 (10. 01. 89) & WO, A, 8807533 & EP, A, 308515	1 - 5				
T	Chemical Abstracts, Abstract No.110(9): 75426s (Arch, Pharm, Cweinheim, Ger), 321(10), 735-8(1988) Garcia-Dominquez, Neftali; Ravina, Enrique; Santana, Lourdes; Teran, Carmen: Garcia-Mera, Gerardo; Orallo, Francisco: Crespo, Manuel; Fontenla, Jose Angel; Abstract of "Pyridazine derivatives. VI. Synthesis and hypotensive activity of 3-hydrazino thieno[2, 3-h] cinnoline and its derivatives")	1 - 5				
A	Chemical Abstracts, Abstract No.103(1): 6254c (J. Heterocycl. Chem., 21(6), 1585-8(1984))	1 - 5				
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁴</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"Z" document member of the same patent family</p> </div> </div>						
IV. CERTIFICATION						
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report				
October 11, 1989 (11. 10. 89)		November 13, 1989 (13. 11. 89)				
International Searching Authority		Signature of Authorized Officer				
Japanese Patent Office						

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

	Abarca, Belen; Ballesteros, Rafael; Jones, Gurnos: Abstract of "The Synthesis of thienocycloheptenoindoles")	1 - 5
A	Chemical Abstracts, Abstract No.102(13): 113328f (Indian J. Chem., Sect. B, 23B(10), 918-25(1984) De, Asish; Brunskill, John S. A.; Jeffrey, Howard: Abstract of "Studies in sulfur heterocycles; part III-syntheses of tricyclic compounds with condensed thiophene rings")	1 - 5

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE '

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers , because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim numbers , because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim numbers , because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

- | | | |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| A | Chemical Abstracts, Abstract No.102(3):
24389j
(J. Chem. Res., synop., (7), 218-19(1984)
Sasaki, Tadashi; Ishibashi, Yukio;
Ohno, Masatomi: Abstract of "Molecular
design by cycloaddition reactions. Part 43.
cycloaddition reactions of silyl enol
ethers of 2-acetylfuran and -thiophene
and related benzo analogs") | 1 - 5 |
| A | Chemical Abstracts, Abstract No.100(5):
33904j
(Heterocycles 20(10), 1933-6(1983)
Sasaki, Tadashi; Ishibashi, Yukio; | 1 - 5 |

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Ohno, Masatomi: Abstract of "Molecular design by cycloaddition reaction. Part 41. Remarkable difference in the cycloaddition reactivity between 2-(1-trimethylsilyloxyvinyl) furan and -thiophene")

A US, A, 3816437 (Sandoz-Wander, Inc.)
11 June 1974 (11. 06. 74)
(Family : none)

1 - 5

A US, A, 3631174 (Americancyananid Co.)
28 December 1971 (28. 12. 71)
(Family : none)

1 - 5

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers ..., because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest:

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	Chemical Abstracts, Abstract No.76(17): 94565g (J. Med. chem., 14(11), 1127-9(1971) Remers William A.; Gibbs, Gabriel J.; Poletto. John F.; Weiss, Martin J.; Abstract of " Tricyclic heterocycles derived from 4-oxo-4,5,6,7-tetrahydro- thianaphthenes")	1 - 5
A	Chemical Abstracts, Abstract No.72(9): 43328s (J. Chem. Soc. C, (19), 2750-4(1969) Drewry, D. T.; Scrowston R. M.: Abstract of "Bromination and Vilsmeier-	1 - 5

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers ..., because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers ..., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers ..., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A

Chemical Abstracts, Abstract No.102(17):
149129f
(J. Hetero cycl. Chem., 21(5), 1505-8(1984)
Arribas, Enrique; Vega, Salvador:
Abstract of "Derivatives of benzo[4,5]
cyclohepta[1,2-b]thiophene. 3, Synthesis
of 2,3,6,7-tetrahydro-3-oxobenzo[1,2]
cyclohepta[3,4,5-hi]thieno[3,4-c]
pyridine and 2,3,7,8-tetrahydro-3-
oxothieno[2,1-b]cyclohepta[5,6,7-de]
isoquinoline")

1 - 5

Y. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers , because they relate to subject matter not required to be searched by this Authority, namely:

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	EP, A, 497896 (Consejo Superior de Investigaciones Cientificas) 16 November 1981 (16. 11. 81) (Family : none) (Chemical Abstracts, Abstract No.97(1): 6278w)	1 - 5
---	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.